Immune Boost Capital backs Orthrus Therapeutics in autoimmune disease push
Immune Boost Capital has invested in Orthrus Therapeutics, a Boston Children’s Hospital spinout developing antigen-specific immune tolerance therapies for autoimmune disease, with a focus on rheumatoid arthritis. The deal adds a board observer and scientific adviser from IBC as both companies look to move beyond broad immunosuppression toward durable remission.
Why it matters: - The investment supports a precision approach to autoimmune disease that aims to restore immune tolerance instead of broadly suppressing the immune system. - Orthrus Therapeutics is targeting conditions such as rheumatoid arthritis, where current therapies can leave patients managing symptoms and side effects over the long term. - The platform could reduce infection risk, treatment burden and other trade-offs linked to broad immunosuppressive drugs if the approach works as intended.
What happened: - Immune Boost Capital, the venture investment arm of the Arthritis National Research Foundation, announced an investment in Orthrus Therapeutics. - Orthrus Therapeutics is a Boston Children’s Hospital spinout developing a new class of precision therapies for autoimmune disease. - Dr. Sai Nandi, Immune Boost Capital’s Founding Principal, will join the Orthrus Board of Directors as an observer and serve on the company’s Scientific Advisory Board.
The details: - Orthrus is building an antigen-specific immune tolerance platform designed to address the root cause of autoimmune disease. - The company’s approach uses VHH-conjugates to selectively suppress disease-driving T cells. - The platform also expands regulatory T cells, which help restore immune balance. - Orthrus says the approach additionally targets pathogenic B cells to reduce disease-causing antibodies while preserving the patient’s broader antibody repertoire. - Immune Boost Capital said the funds will help Orthrus advance its technology and expand its platform across autoimmune indications. - IBC operates as a philanthropic evergreen fund, with returns reinvested into future innovation. - IBC also runs an IBC Venture Studio that works with founders and academic spinouts on strategy, operations and go-to-market planning. - Orthrus Therapeutics is developing VHH-drug conjugates, or VDCs, to restore antigen-specific immune tolerance, with an initial focus on T cell-driven autoimmune diseases. - Orthrus says the platform has the potential to support immune reset, long-term remission or even cures. - More information is available in Immune Boost Capital's announcement and Orthrus Therapeutics' announcement.
Between the lines: - The investment fits IBC’s mission-driven model of backing therapies for rheumatic and autoimmune disease while recycling returns into future deals. - Dr. Nandi’s board and advisory roles signal a hands-on investment approach that goes beyond capital. - Orthrus is trying to position itself in a competitive field by aiming at antigen-specific tolerance, a more targeted strategy than standard immunosuppression.
What's next: - Orthrus will use the new capital to keep advancing its platform and build out programs for autoimmune disease. - Dr. Nandi’s board observer and advisory role gives IBC a formal channel to influence strategy as Orthrus develops. - If the platform succeeds, Orthrus could move toward durable remission with fewer side effects and fewer treatment burdens for patients.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Today in Healthcare
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.